The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.
TRAIN-HEART brings together leading academic teams and (biotech) companies covering various disciplines ranging from fundamental research to clinical pharmacology and gene therapy to drug delivery applications, have teamed up in the European Union.
The TRAIN-HEART network aims to gain viable insight in the pathogenesis of ischemic heart failure which will serve as a basis for drug discovery and drug delivery efforts that aim to therapeutically target specific molecules and mechanisms within cardiomyocytes for the treatment of ischemic heart failure.
If you have any questions you can fill in the form or mail us directly: info@train-heart.eu.
News
RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy personalised medicines, and treatment of genetic, infectious and chronic diseases. Furthermore, the recent advent of CRISPR, an RNA-guided gene-editing technology, as well as new strides in the delivery of messenger RNA transcribed in vitro, have triggered a major expansion of the RNA-therapeutics field.
The 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics with the latest case studies on advanced mRNA technologies, oligonucleotide delivery, therapeutic applications and future trends and innovations.
The 12th annual RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to gain an expert and holistic view on the latest developments in the industry, upcoming regulatory updates and industry implications. Prof. Thomas Thum (Hannover) is one of the invited speakers. For more details about the conference programme and speakers, you can access the conference website HERE .
Tue, 10 November
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 813716.
Copyright © 2020
